Format

Send to

Choose Destination
Cancer Epidemiol. 2014 Dec;38(6):748-56. doi: 10.1016/j.canep.2014.09.003. Epub 2014 Oct 8.

Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China).

Author information

1
Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain. Electronic address: bea.iconcologia@gmail.com.
2
Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain; CIBER Epidemiología y Salud Pública, CIBERESP, Barcelona, Spain. Electronic address: lalemany@iconcologia.net.
3
Hospital General de México, México. Electronic address: ruizalonso01@aol.com.
4
Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain. Electronic address: stous@iconcologia.net.
5
Hospital Dr. Hélio Angotti, Uberaba, Brazil. Electronic address: lapc@mednet.com.br.
6
Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain. Electronic address: lbruni@iconcologia.net.
7
Cancer Prevention and Relief Society, Raipur, India. Electronic address: dr.ashajain@smsaraipur.co.in.
8
International Agency for Research on Cancer, Lyon, France. Electronic address: clifford@iarc.fr.
9
National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: qiaoy@cicams.ac.cn.
10
Global Health Outcomes, Merck & Co., Inc., West Point, PA USA. Electronic address: thomas_weiss@merck.com.
11
Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain. Electronic address: x.bosch@iconcologia.net.
12
Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain; CIBER Epidemiología y Salud Pública, CIBERESP, Barcelona, Spain. Electronic address: s.sanjose@iconcologia.net.

Abstract

BACKGROUND:

We estimated the potential impact of an investigational 9-valent human papillomavirus (HPV) vaccine (HPVs 6/11/16/18/31/33/45/52/58) in HPV-related cervical disease in Brazil, Mexico, India and China, to help to formulate recommendations on cervical cancer prevention and control.

METHODS:

Estimations for invasive cervical cancer (ICC) were based on an international study including 1356 HPV-positive cases for the four countries altogether, and estimations for precancerous cervical lesions were extracted from a published meta-analysis including 6 025 HPV-positive women from the four mentioned countries. Globocan 2012 and 2012 World Population Prospects were used to estimate current and future projections of new ICC cases.

RESULTS:

Combined proportions of the 9 HPV types in ICC were 88.6% (95%CI: 85.2-91.3) in Brazil, 85.7% (82.3-88.8) in Mexico, 92.2% (87.9-95.3) in India and 97.3% (93.9-99.1) in China. The additional HPV 31/33/45/52/58 proportions were 18.8% (15.3-22.7) in Brazil, 17.6% (14.2-21.2) in Mexico, 11.3% (7.5-16.1) in India and 11.9% (7.5-17.2) in China. HPV6 and 11 single types were not identified in any of the samples. Proportion of the individual 7 high risk HPV types included in the vaccine varied by cytological and histological grades of HPV-positive precancerous cervical lesions. HPV 16 was the dominant type in all lesions, with contributions in low grade lesions ranging from 16.6%(14.3-19.2) in Mexico to 39.8% (30.0-50.2) in India, and contributions in high grade lesions ranging from 43.8% (36.3-51.4) in Mexico to 64.1% (60.6-67.5) in Brazil. After HPV 16, variations in other majors HPV types were observed by country, with an under representation of HPV 18 and 45 compared to ICC.

CONCLUSION:

The addition of HPVs 31/33/45/52/58 to HPV types included in current vaccines could increase the ICC preventable fraction in a range of 12 to 19% across the four countries, accounting the 9-types altogether 90% of ICC cases. Assuming the same degree of efficacy of current vaccines, the implementation of the 9-valent HPV vaccine in Brazil, Mexico, India and China would substantially impact on the reduction of the world cervical cancer burden.

KEYWORDS:

Brazil; China; Epidemiology; Genotype; Human papillomavirus; Human papillomavirus vaccines; India; Mexico; Uterine cervical neoplasms

PMID:
25305098
DOI:
10.1016/j.canep.2014.09.003
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center